Dihexa for brain fog and ADHD: what the evidence actually says

What did @genxshopfinds76 actually say?

Jen, a self-described nurse practitioner, claims dihexa is a prescription peptide that "repair[s] and regrow[s] synaptic connections" and has "been shown in preclinical studies to outperform traditional Alzheimer's drugs by a mile." She pitches it as a solution for brain fog, memory lapses, and what she calls "post-covid connective fatigue," and directs viewers to her telehealth practice in Ohio. That's a lot of weight to put on a compound with almost no human data behind it.

She does get the prescription-only framing right, noting it "should be compounded through licensed 503A pharmacy" rather than bought off the internet. That's a meaningful distinction in a space full of gray-market peptide vendors. But the clinical extrapolations she makes from preclinical rodent work are where this video goes off the rails.

Does the science back this up?

The short answer: barely, and only in animals. Dihexa is an angiotensin IV analog originally developed by Joseph Harding and colleagues at Washington State University. The preclinical data is genuinely interesting. But "interesting in rats" and "proven for humans" are very different sentences.

The foundational study (Benoist et al., 2011, Journal of Pharmacology and Experimental Therapeutics) showed dihexa enhanced spatial learning in aged rodents with induced cognitive impairment. A follow-up from the same group (McCoy et al., 2013, Clinical Science) found it promoted synaptogenesis through hepatocyte growth factor pathways. The "outperforms Alzheimer's drugs" claim appears to trace back to comparisons with scopolamine-impaired rodent models, not human clinical trials of approved dementia drugs. No Phase 1, Phase 2, or Phase 3 human trials for dihexa appear in ClinicalTrials.gov as of early 2025. Translating rodent cognition data to humans has a notoriously poor track record in neurology.

What did they get wrong (or right)?

Wrong: framing preclinical animal data as evidence sufficient to recommend this to people with ADHD or post-COVID symptoms. That leap is not supported. Saying dihexa "outperforms traditional Alzheimer's drugs" without clarifying this comes exclusively from animal models is, at minimum, misleading to a TikTok audience.

Also unverifiable: the specific claims about creativity and "long-term learning and processing speed." These don't appear in published peer-reviewed literature. They circulate in biohacking forums and compounding pharmacy marketing copy, neither of which is a clinical source.

What she got right: dihexa is not an over-the-counter supplement. It requires compounding and, in a compliant telehealth model, a prescription following a proper consultation. She correctly identifies it as a 503A compounded product, not an FDA-approved drug. That framing matters. She also avoids quoting specific doses, which is the correct approach on a public social platform.

What should you actually know?

Dihexa is a genuinely novel research compound with a plausible mechanism, an angiotensin IV receptor agonist that appears to upregulate HGF/c-Met signaling involved in synaptic plasticity. That is worth watching. It is not worth treating as a clinically validated therapy for ADHD, brain fog, or post-COVID cognitive symptoms based on what exists in the literature right now.

Post-COVID cognitive impairment is a real and serious condition affecting a meaningful share of long-COVID patients (Davis et al., 2023, Nature Reviews Microbiology). It deserves evidence-based treatment, not a peptide with zero human trial data. Anyone considering dihexa through a telehealth provider should ask directly: what human safety data do you have, what monitoring protocol are you using, and what happens if I experience adverse effects from a compound with no established human pharmacokinetic profile?

• Dihexa has no published human clinical trials as of early 2025.
• The "outperforms Alzheimer's drugs" claim comes from scopolamine-impaired rodent models, not human comparisons.
• 503A compounding is the legal pathway, but legal does not mean clinically validated.
• Post-COVID cognitive symptoms warrant evaluation by a neurologist or specialist before pursuing experimental peptides.
• The HGF/c-Met mechanism is scientifically plausible but unproven in humans.